High-yield overview
FDG-PET for staging, response assessment and recurrence in bone and soft tissue tumours
—Tracer
18F- FDG (fluorodeoxyglucose)
—Uptake Time
60minutes post-injection
18Half-life F-
110minutes
—SUV Threshold
2.5SUVmax often used as cut-off
PET-CT Applications in Oncology
Staging: Whole body assessment for metastases
Response: Pre and post-treatment comparison
Recurrence: Detection of local or distant relapse
Biopsy guidance: Target metabolically active areas
Key: PET-CT is most valuable for high-grade malignancies and systemic staging
Critical Must-Knows
- FDG uptake reflects glucose metabolism (Warburg effect)
- High-grade tumours show higher FDG uptake than low-grade
- SUVmax is quantitative measure of uptake intensity
- PET-CT combines metabolic and anatomic information
- Used for staging, response assessment, and recurrence detection
Clinical Pearls
- “Brain has high physiological FDG uptake (limits assessment)
- “Blood glucose must be controlled (less than 11 mmol/L)
- “False positives: infection, inflammation, recent surgery
- “Response: greater than 40% SUV decrease = metabolic response
- “Low-grade sarcomas may have minimal FDG uptake
Clinical Warning
PET-CT is increasingly used in orthopaedic oncology. Know that FDG uptake reflects glucose metabolism, not malignancy directly. Understand the indications (staging, response, recurrence) and limitations (false positives with infection/inflammation, low sensitivity for low-grade tumours).
FDG-PET Principles
Warburg Effect
Malignant cells preferentially use glycolysis for energy (even in presence of oxygen). This increased glucose uptake is the basis for FDG-PET imaging. FDG (fluorodeoxyglucose) is a glucose analogue that is taken up by cells but cannot be metabolised, becoming trapped. Higher-grade, more aggressive tumours typically have higher glucose metabolism and FDG uptake.
| Step | Timing | Requirements |
|---|---|---|
| Patient preparation | 4-6 hours fasting | Blood glucose less than 11 mmol/L |
| FDG injection | Time 0 | 4-5 MBq/kg IV |
| Uptake period | 60 minutes | Rest, avoid talking/chewing |
| PET acquisition | 60 minutes post-injection | Whole body or regional |
| CT acquisition | Simultaneous or sequential | Low-dose for attenuation/localisation |
Mnemonic
SUV = Standardised Uptake ValueSUV Interpretation
Q
Quantitative measure of FDG uptake
S
SUVmax: Maximum value in ROI (most commonly reported)
S
SUVmean: Average value in ROI
H
Higher SUV generally correlates with higher grade
T
Threshold varies but greater than 2.5 often used
Hook:SUV is affected by blood glucose level, body habitus, and timing - standardise conditions for response assessment
Mnemonic
FIB GRABCauses of False-Positive FDG Uptake
F
F - Fracture / healing callus
I
I - Infection (osteomyelitis, septic arthritis)
B
B - Brown fat (symmetric, CT-negative)
G
G - Granulation / post-surgical inflammation
R
R - Recent biopsy or radiotherapy
A
A - Arthritis / active inflammation
B
B - Benign FDG-avid lesions (GCT, fibrous dysplasia)
Hook:Always correlate FDG uptake with history and CT/MRI morphology - metabolic activity is not specific for malignancy
Indications in Orthopaedic Oncology
| Tumour Type | Role of PET-CT | Notes |
|---|---|---|
| Osteosarcoma | Detect lung/distant metastases, skip lesions | Complements bone scan, CT chest |
| Ewing sarcoma | Systemic staging, marrow involvement | Very FDG-avid |
| Soft tissue sarcoma | Stage high-grade lesions, detect nodal/distant disease | Low-grade may not be FDG-avid |
| Chondrosarcoma | Grade assessment, dedifferentiation | Low-grade shows low uptake |
| Metastatic disease | Whole body survey, unknown primary | Complementary to bone scan |
Specific Tumour Applications
| Tumour | FDG Avidity | Clinical Implications |
|---|---|---|
| Osteosarcoma | High | SUV correlates with histological response |
| Ewing sarcoma | Very high | Excellent for staging and response |
| High-grade STS | High | SUV predicts grade and outcome |
| Low-grade STS | Low to moderate | May not be reliably detected |
| Chondrosarcoma G1 | Low | Difficult to differentiate from enchondroma |
| Chondrosarcoma G2-3 | Moderate to high | Increased uptake suggests higher grade |
| GCT | Variable | Not reliably FDG-avid |
| Myeloma | Variable | FDG-PET useful for treatment response |
Osteosarcoma
PET-CT useful for detecting skip lesions, distant metastases, and response assessment. Decrease in SUV post-chemotherapy correlates with histological necrosis (good prognostic factor). Sensitivity for lung metastases similar to CT chest.
Soft Tissue Sarcoma
High-grade lesions are FDG-avid; SUVmax greater than 6 predicts higher grade. Low-grade sarcomas (well-differentiated liposarcoma, low-grade fibromyxoid sarcoma) may have minimal uptake. PET helps detect nodal involvement in selected subtypes.
Limitations and Pitfalls
| Category | Cause | Mitigation |
|---|---|---|
| False positive | Infection/inflammation | Clinical correlation, follow-up |
| False positive | Recent surgery/biopsy | Wait 4-6 weeks post-procedure |
| False positive | Fracture healing | Correlate with history |
| False positive | Brown fat uptake | Patient warming, beta-blockers |
| False negative | Low-grade tumour | Limited sensitivity, MRI better |
| False negative | Small lesions (less than 1cm) | Resolution limits |
| False negative | Hyperglycaemia | Control glucose, repeat if needed |
Key Limitations
PET-CT cannot reliably differentiate benign from malignant in all cases - infection, inflammation, and healing all cause FDG uptake. Low-grade malignancies may not be FDG-avid. Small lesions (less than 1cm) may be missed due to resolution limits. Brain assessment limited by high physiological uptake. Must control blood glucose for accurate results.
Comparison with Other Modalities
| Feature | Bone Scan | PET-CT | MRI |
|---|---|---|---|
| Mechanism | Osteoblast activity | Glucose metabolism | Tissue characterisation |
| Whole body | Yes | Yes | Limited (WB-MRI emerging) |
| Anatomic detail | Poor | Good (CT component) | Excellent |
| Lytic metastases | May be cold | Usually positive | Positive (marrow) |
| Soft tissue | Limited | Good | Excellent |
| Response assessment | Limited | Good (SUV) | Moderate |
| Availability | Widely available | Limited centres | Widely available |
| Cost | Lower | Higher | Moderate |
| Entity | Typical SUVmax / Pattern | Discriminating Features |
|---|---|---|
| High-grade sarcoma | High (often greater than 6), focal intense | Soft tissue mass, cortical destruction, growth on serial imaging |
| Low-grade sarcoma / atypical lipomatous tumour | Low to moderate (often under 3) | May be PET-negative; MRI fat signal, slow growth |
| Infection / osteomyelitis / septic arthritis | Moderate to high, can mimic tumour | Clinical signs, raised inflammatory markers, marrow oedema, rim enhancement |
| Post-surgical / post-biopsy inflammation | Diffuse, linear uptake along tract | History; resolves over weeks (wait 4 to 6 weeks before imaging) |
| Fracture / healing callus | Moderate fusiform uptake at fracture line | History of trauma, fracture line on CT, settles with time |
| Brown fat (supraclavicular, paraspinal) | Symmetric, CT-negative fat density | Patient warming and benzodiazepine/beta-blocker reduce uptake |
| Reactive / inflammatory lymph node | Mild to moderate, oval, fatty hilum | Preserved hilum; biopsy if discordant with primary |
| Benign bone lesion (GCT, fibrous dysplasia, osteoid osteoma) | Variable, can be markedly FDG-avid | Characteristic CT/MRI morphology prevents over-call of malignancy |
Controversies & Areas of Uncertainty
No universal SUV cut-off
SUVmax is not standardised across scanners, reconstruction algorithms, uptake time, or patient body habitus. A single numeric threshold (e.g. 2.5) cannot reliably separate benign from malignant or low-grade from high-grade across all centres. PERCIST exists precisely because absolute SUV is not transferable between time points unless conditions are tightly controlled.
Cartilage tumours: the grey zone
The overlap between enchondroma and grade 1 (atypical cartilaginous tumour) chondrosarcoma is the central unresolved problem. Very low SUVmax favours benign and high SUVmax favours grade 2/3, but the benign-to-G1 boundary remains unreliable on PET alone, and histology/MRI/clinical correlation is mandatory.
Prognostic vs predictive value
Whether baseline or interim SUV should change treatment (risk-adapted chemotherapy) is unproven. Studies show association with histological necrosis and survival, but no randomised trial has demonstrated that altering therapy on PET findings improves outcomes. PET-guided treatment escalation remains investigational.
Surveillance role unsettled
Routine PET-CT surveillance after sarcoma resection is not supported by high-level evidence; CT chest plus local MRI remain standard. PET is best reserved for problem-solving (equivocal recurrence, rising markers, symptomatic patients) rather than scheduled follow-up, balancing radiation dose and false positives.
Evidence
Evidence
PERCIST 1.0: standardised metabolic response criteria
O JH, Lodge, Wahl • Radiology (2016)
Key Findings:
- Practical guide to PET Response Criteria in Solid Tumors (PERCIST 1.0), defining quality control needed to compare FDG-PET across time points.
- Response is measured using SUL peak (lean-body-mass corrected) in a reference lesion, not raw SUVmax, to reduce variability.
- Defines complete, partial, stable and progressive metabolic disease and clarifies measurement of unequivocal progression.
Clinical implication: Use PERCIST methodology (controlled glucose, fixed uptake time, same scanner) so a reported SUV change reflects biology, not technique.
Evidence
FDG-PET correlates with histological necrosis in osteosarcoma
Hamada, Tomita, Inoue, et al • Ann Nucl Med (2009)
Key Findings:
- 11 osteosarcoma patients had FDG-PET before and after neoadjuvant chemotherapy correlated with histological necrosis.
- Post-chemotherapy SUV (SUV2) was much lower in good responders (mean 1.93) than poor responders (5.86); change in tumour size on MRI did not correlate with response.
- An SUV2 under 2.5 had 100% positive and negative predictive value for good histological response in this small series.
Clinical implication: A residual SUVmax that stays high after chemotherapy flags a likely poor responder; metabolic change outperforms size change.
Evidence
Baseline tumour SUV predicts response and survival in bone sarcoma
Palmerini, Colangeli, Nanni, et al • Eur J Nucl Med Mol Imaging (2016)
Key Findings:
- 77 patients with localised Ewing sarcoma (45) and osteosarcoma (32) staged with FDG-PET/CT.
- Lower baseline SUVmax (under 6) predicted a higher good-response rate (72% vs 30% in Ewing; 64% vs 29% in osteosarcoma).
- Baseline SUVmax was the only independent pre-treatment prognostic factor for event-free survival on multivariate analysis.
Clinical implication: Baseline metabolic activity carries independent prognostic weight and can help stratify high-risk localised bone sarcoma.
Evidence
SUVmax stratifies grade and prognosis in soft tissue sarcoma
Sambri, Bianchi, Longhi, et al • Nucl Med Commun (2019)
Key Findings:
- 50 adults with primary high-grade extremity soft tissue sarcoma and preoperative FDG-PET; mean SUVmax 12.9 (range 2.2 to 33.4).
- Lower SUVmax (under 10.3) was associated with better overall survival and lower local recurrence.
- Myxoid liposarcoma and synovial sarcoma were consistently low-uptake, limiting PET sensitivity in these subtypes.
Clinical implication: High SUVmax marks biologically aggressive disease, but a low value does not exclude sarcoma in classically low-avidity histologies.
Evidence
FDG-PET differentiates benign from malignant chondroid tumours
Subhawong, Winn, Shemesh, Pretell-Mazzini • Skeletal Radiol (2017)
Key Findings:
- Systematic review of 8 studies and 166 chondroid lesions correlating SUVmax with histological grade.
- Mean SUVmax was lower for benign (1.6) than malignant (4.4) lesions and rose with grade (grade 0/1 = 2.0 vs grade 2/3 = 6.0).
- An SUVmax of 4.4 or greater was 99% specific for grade 2/3 chondrosarcoma.
Clinical implication: Very low SUV supports a benign cartilage lesion and high SUV suggests high-grade chondrosarcoma, but the enchondroma-to-G1 boundary stays unreliable.
Evidence
Meta-analysis: PET/CT accuracy in chondrosarcoma diagnosis and grading
Zhang, Xi, Li, Yuan, Dong • J Orthop Surg Res (2020)
Key Findings:
- Meta-analysis of 12 studies evaluating FDG-PET/CT for chondrosarcoma diagnosis and grading.
- Pooled PET/CT sensitivity 0.94 and specificity 0.89 for diagnosing chondrosarcoma.
- SUVmax separated low- from intermediate/high-grade chondrosarcoma but was limited at the benign-vs-G1 and G2-vs-G3 boundaries.
Clinical implication: PET/CT is highly accurate for confirming and grading chondrosarcoma overall, yet cannot replace histology at the diagnostically critical low-grade margin.
Evidence
FDG-PET/CT outperforms bone scintigraphy for skeletal metastases in paediatric sarcoma
Harrison, Parisi, Shulkin • Semin Nucl Med (2017)
Key Findings:
- Review of FDG-PET/CT in paediatric osteosarcoma, Ewing sarcoma and rhabdomyosarcoma.
- PET/CT has consistently better sensitivity and specificity than bone scintigraphy for detecting skeletal metastases.
- Its value for pulmonary metastases is limited (CT chest remains superior for small lung nodules) and its prognostic role outside osteosarcoma is unproven.
Clinical implication: PET/CT is the preferred whole-body tool for bone metastases in sarcoma, but always pair it with a dedicated CT chest for lung disease.
Guidelines, Registries & Global Practice
| Body | Position on FDG-PET/CT | Practical Point |
|---|---|---|
| NCCN (US) | Recommended for staging high-grade STS and bone sarcoma; option for restaging and equivocal recurrence | CT chest still required for lung metastases |
| ESMO / EURACAN (Europe) | PET-CT may aid staging, grading and response assessment in selected sarcomas | Emphasises management within sarcoma reference centres |
| NICE / BSG (UK) | Reserved for problem-solving; not routine surveillance | MRI primary site plus CT chest remain core staging |
| RCR / EANM (imaging societies) | Standardised acquisition and PERCIST-style reporting encouraged | Fasting, glucose control, fixed uptake time mandatory |
| SIOP / COG (paediatric) | Increasing use for skeletal staging in Ewing and osteosarcoma | Preferred over bone scan for marrow/bone disease |
Global epidemiology context
Primary bone sarcomas are rare (roughly 0.8 to 1 per 100,000 per year), with osteosarcoma and Ewing sarcoma peaking in adolescents and young adults and a second osteosarcoma peak in older adults. Soft tissue sarcomas are commoner (about 4 to 5 per 100,000 per year). These low incidences underpin the global recommendation to centralise diagnosis and imaging in specialist sarcoma units.
High- vs limited-resource practice
PET-CT scanners and on-site cyclotron/FDG supply are concentrated in high-income settings. Where access is limited, bone scintigraphy plus regional MRI and CT chest remain the backbone of staging. FDG's 110-minute half-life constrains transport distance from production, so availability is a genuine driver of practice variation worldwide rather than a difference in clinical preference.
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
Viva scenarioStandard
Clinical prompt
“A 16-year-old with newly diagnosed osteosarcoma of the distal femur is being staged. The oncologist requests PET-CT.”
Practical approach
PET-CT in osteosarcoma staging has several roles: (1) Detection of skip lesions - separate tumour foci in the same bone, which affect surgical planning and prognosis. PET may detect skip lesions not seen on MRI. (2) Distant metastases - lung metastases (though CT chest is also needed for small nodules), bone metastases in other sites. (3) Baseline SUVmax - establishes pre-treatment metabolic activity for comparison after neoadjuvant chemotherapy. (4) Response prediction - higher pre-treatment SUV paradoxically associated with better response to chemotherapy. I would look for: primary tumour FDG uptake and extent, any separate foci in the same bone (skip lesions), other bone involvement, nodal disease, and lung lesions.
Key clinical points
Skip lesions affect staging and prognosis
Whole body assessment for metastases
Baseline SUV for response comparison
Complement with MRI (local extent) and CT chest (small lung mets)
High pre-treatment SUV may predict response
Common pitfalls
Relying only on PET for lung metastases (small nodules may be missed)
Not knowing about skip lesion detection
Forgetting baseline SUV importance for response
Further questions
“How would you assess treatment response with PET? What degree of SUV decrease indicates good response?”
Viva scenarioChallenging
Clinical prompt
“A patient with known high-grade soft tissue sarcoma of the thigh has PET-CT showing intense uptake in the primary tumour (SUVmax 12) and a 1.5cm inguinal lymph node with SUVmax 4.”
Practical approach
The primary tumour shows high FDG uptake (SUVmax 12), consistent with high-grade sarcoma. The inguinal lymph node with SUVmax 4 is concerning for nodal metastasis, though lymph node metastases are uncommon in most soft tissue sarcomas (less than 5% overall). However, certain histological subtypes have higher nodal metastasis rates: synovial sarcoma, epithelioid sarcoma, clear cell sarcoma, rhabdomyosarcoma, and angiosarcoma. The FDG-avid node should be biopsied or closely monitored. If confirmed as metastatic, this upstages the disease and affects prognosis and treatment planning. Alternative explanations for the node include reactive lymphadenopathy (infection, inflammation), so tissue confirmation is important before assuming metastatic disease.
Key clinical points
Most STS have low rate of nodal mets (less than 5%)
Exceptions: synovial, epithelioid, clear cell, rhabdo, angiosarcoma
SUV 4 in node is suspicious but not diagnostic
Biopsy or close monitoring recommended
Nodal mets affect staging and prognosis
Common pitfalls
Assuming all FDG-avid nodes are metastatic
Not knowing which STS subtypes metastasise to nodes
Not recommending tissue confirmation
Further questions
“What is the prognosis for soft tissue sarcoma with nodal metastases? How would this finding change your treatment approach?”
Viva scenarioChallenging
Clinical prompt
“A patient with a cartilage tumour in the proximal humerus has PET-CT. The lesion shows SUVmax of 3.5.”
Practical approach
FDG-PET can help differentiate benign from malignant cartilage lesions based on metabolic activity. Generally: Enchondromas have low FDG uptake (SUVmax typically less than 2). Low-grade (G1) chondrosarcomas have low to moderate uptake (often SUVmax 2-4). Higher-grade (G2-3) chondrosarcomas show higher uptake (SUVmax greater than 4-5). This patient's SUVmax of 3.5 is in an intermediate zone and concerning for at least low-grade chondrosarcoma. However, there is overlap between enchondroma and G1 chondrosarcoma, making PET alone insufficient for definitive diagnosis. Clinical context matters: symptoms (pain without fracture), location (axial vs appendicular), size, and imaging features (cortical destruction, soft tissue mass). This lesion warrants close follow-up or biopsy, as the SUV suggests it may not be a simple enchondroma.
Key clinical points
Enchondroma: Low SUV (typically less than 2)
G1 chondrosarcoma: Low-moderate SUV (overlap zone)
G2-3 chondrosarcoma: Higher SUV (greater than 4-5)
SUV 3.5 is intermediate, concerning for low-grade malignancy
Clinical and imaging correlation essential
Common pitfalls
Using SUV alone to diagnose
Not recognising overlap between enchondroma and low-grade CS
Dismissing intermediate SUV as benign
Further questions
“What other imaging features distinguish enchondroma from chondrosarcoma? When would you recommend biopsy?”
Exam day cheat sheet
PET-CT in Orthopaedic Oncology
FDG-PET Principles
- FDG = Fluorodeoxyglucose (glucose analogue)
- Warburg effect: Tumours use glycolysis
- Higher grade = higher SUV generally
- SUVmax = maximum standardised uptake value
Indications
- Staging: Metastases, skip lesions
- Response: SUV decrease greater than 30-40%
- Recurrence: Symptomatic patients
- Biopsy guidance: Target active areas
FDG Avidity by Tumour
- High: Osteosarcoma, Ewing, high-grade STS
- Variable: Chondrosarcoma (grade-dependent)
- Low: Low-grade STS, enchondroma
Limitations
- False +: Infection, inflammation, surgery
- False -: Low-grade tumours, small lesions
- Glucose control essential
- Cannot replace biopsy for diagnosis